4-(4-nitro-phenyl)-2-oxo-1,2-dihydro-pyridine-3-carbonitrile | 960071-02-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-(4-nitro-phenyl)-2-oxo-1,2-dihydro-pyridine-3-carbonitrile
• 英文别名: 1,2-Dihydro-4-(4-nitrophenyl)-2-oxo-3-pyridinecarbonitrile；4-(4-nitrophenyl)-2-oxo-1H-pyridine-3-carbonitrile
• CAS: 960071-02-7
• 化学式: C₁₂H₇N₃O₃
• 分子量: 241.206
• InChiKey: DJJNIXWIUCTBBX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  98.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-[1-(4-硝基苯基)亚乙基]丙二腈 在 硫酸 、 水 、 溶剂黄146 作用下， 反应 2.0h， 生成 4-(4-nitro-phenyl)-2-oxo-1,2-dihydro-pyridine-3-carbonitrile
  参考文献：
  名称：

  WO2007/144203

  摘要：

  公开号：

文献信息

• Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them.
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP1867648A1

  公开（公告）日：2007-12-19

  The invention relates to substituted pyrazolopyridines according to the general formula (1) : in which A, B, D, E, Ra, R1, R2, R3, R4, R5 and q are as defined in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted pyrazolopyridine compounds, to methods of preparing said substituted pyrazolopyridines, as well as to uses thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signaling.

  该发明涉及根据通式（1）所示的取代吡唑吡啶化合物：其中A、B、D、E、Ra、R1、R2、R3、R4、R5和q如权利要求中所定义的，以及其盐，包括所述取代吡唑吡啶化合物的药物组合物，制备所述取代吡唑吡啶的方法，以及用于制造用于治疗血管生长失调疾病或伴随血管生长失调的疾病的药物组合物的用途，其中这些化合物有效干扰Tie2信号传导。
• SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME
  申请人：Hartung Ingo

  公开号：US20080058326A1

  公开（公告）日：2008-03-06

  The invention relates to substituted pyrazolopyridines according to the general formula (I): in which A, B, D, E, R a , R 1 , R 2 , R 3 , R 4 , R 5 and q are as defined in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted pyrazolopyridine compounds, to methods of preparing said substituted pyrazolopyridines, as well as to uses thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.

  本发明涉及一般式（I）的取代吡唑吡啶化合物，其中A、B、D、E、Ra、R1、R2、R3、R4、R5和q如权利要求所定义，并且其盐，以及包括所述取代吡唑吡啶化合物的制药组合物，制备所述取代吡唑吡啶化合物的方法，以及将其用于制造治疗失调血管生长疾病或伴随失调血管生长的疾病的制药组合物的用途，其中这些化合物有效地干扰Tie2信号传导。
• SUBSTITUTED ARYLPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME
  申请人：Hartung Ingo

  公开号：US20080064707A1

  公开（公告）日：2008-03-13

  The invention relates to substituted arylpyrazolopyridines according to the general formula (I): in which A, B, D, E, R a , R 1 , R 2 , R 3 , R 4 , R 5 and q are as defined in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted arylpyrazolopyridines, to methods of preparing said substituted arylpyrazolopyridines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.

  本发明涉及一种按照通式(I)所示的取代芳基吡唑吡啶化合物，其中A、B、D、E、Ra、R1、R2、R3、R4、R5和q的定义如权利要求书中所述，以及其盐。本发明还涉及包含所述取代芳基吡唑吡啶化合物的药物组合物，制备所述取代芳基吡唑吡啶化合物的方法以及其用于制造用于治疗失调的血管生长或伴随失调的血管生长疾病的药物组合物的用途，其中该化合物有效地干扰Tie2信号传导。
• Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP1870410A1

  公开（公告）日：2007-12-26

  The invention relates to substituted arylpyrazolopyridines according to the general formula (1) : in which A, B, D, E, Ra, R1, R2, R3, R4, R5 and q are as defined in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted arylpyrazolopyridines, to methods of preparing said substituted arylpyrazolopyridines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.

  本发明涉及通式（1）的取代芳基吡唑并吡啶： 其中 A、B、D、E、Ra、R1、R2、R3、R4、R5 和 q 如权利要求中定义，及其盐类，涉及包含所述取代的芳基吡唑并吡啶的药物组合物，涉及制备所述取代的芳基吡唑并吡啶的方法，以及使用其制造药物组合物，用于治疗血管生长失调疾病或伴随血管生长失调的疾病，其中所述化合物可有效干扰 Tie2 信号。
• Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them
  申请人：Bayer Intellectual Property GmbH

  公开号：EP2061790B1

  公开（公告）日：2014-08-13